Loss of Neurologic Reserve in Progressive Multiple Sclerosis
A Paradigm Shift?
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published June 18, 2021.
Article Versions
- Previous version (June 18, 2021 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Joep Killestein, MD, PhD and
- Maria Liguori, MD, PhD
- Joep Killestein, MD, PhD and
Steering committees Roche and Biogen trials
NONE
Speaker honoraria Biogen, Novartis, TEVA, Merck, Roche
Editor of the official scientific journal of the Dutch Society of Neurology, the Dutch Society of Neurosurgeons and the Society of Flemish Neurologists (Tijdschrift voor Neurologie en Neurochirurgie). Editorial board MS Journal Editorial board Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have been involved in clinical trials of several companies that market drugs for MS. The past two years Biogen and Roche sponsored trials.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Liguori, MD, PhD
NONE
NONE
NONE
Guest Editor of International Journal of Molecular Sciences - Special Issue "Autoimmunity in the Nervous Systems: Multiple Sclerosis and Beyond" (NO COMPENSATION)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Amsterdam UMC (JK), Vrije Universiteit Amsterdam, Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, the Netherlands; and National Research Council (CNR) (ML), Institute of Biomedical Technologies, Bari Unit, Italy.
- Correspondence
Dr. Killestein j.killestein{at}vumc.nl
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosisC. E. Teunissen, E. Iacobaeus, M. Khademi et al.Neurology, April 13, 2009 -
Review
Multiple Sclerosis Phenotypes as a ContinuumThe Role of Neurologic ReserveTimothy L. Vollmer, Kavita V. Nair, Ian M. Williams et al.Neurology: Clinical Practice, January 29, 2021 -
Views & Reviews
The topographical model of multiple sclerosisA dynamic visualization of disease courseStephen C. Krieger, Karin Cook, Scott De Nino et al.Neurology: Neuroimmunology & Neuroinflammation, September 07, 2016 -
Article
Tissue Transglutaminase Expression Associates With Progression of Multiple SclerosisClaudia Sestito, Cyra E. Leurs, Martijn D. Steenwijk et al.Neurology: Neuroimmunology & Neuroinflammation, April 27, 2021